INNOVACAPNSEInnova Captab Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 7 Nov, 2025 · 17:16 IST

Innova Captab Q2 FY26 results: revenue up about 20 percent, profit dips

Revenue Growth 20pctResults View source PDFExplain this filing

INNOVACAP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.1%Reaction day
₹766.00
prior close
₹748.05
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-2.8% vs market
Pharmaceuticals peers, median of 155sector-0.1%-3.0% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 3.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.7
10m
+0.1
15m
-0.1
30m
+0.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.1-0.4-2.8-0.1-3.0
Next day
-7.1-0.6-6.5-0.7-6.4
2d
-7.0+0.3-7.3+0.4-7.4
3d
-4.0+0.2-4.3+0.0-4.0
4d
-1.7+0.1-1.8+0.4-2.1
5d
-5.0+0.7-5.7+0.3-5.3
1w
-5.6-0.3-5.3-0.7-4.9
15d
-6.8-2.0-4.8-1.4-5.4
1m
-3.5-5.7+2.2-3.8+0.3
2m
-11.0-7.8-3.2-6.2-4.8
3m
-8.1-4.6-3.5-6.7-1.4
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated revenue rose about 20 percent YoY to Rs 3,804 million in Q2 FY26 and to Rs 7,319 million in H1 FY26. However, consolidated PAT fell 15 percent YoY to Rs 297 million in Q2 and 6 percent to Rs 607 million in H1, hit by a sharp jump in finance costs (Rs 83.55 million vs Rs 2.87 million) and depreciation. Standalone revenue grew about 21 percent in Q2. Auditor BS R and Co LLP issued an unmodified review report.

Likely market impact

Revenue growth positive but profitability pressured by rising finance costs and depreciation. Watch margin trajectory in coming quarters.